Healthcare industry reports 106 deals worth $49.7 billion in June 2021

One big-ticket deal contributed 68.4 per cent of total deal value in June 2021

In June 2021, the healthcare industry reported 106 deals worth $49.7 billion as compared to the last 12-month average (June 2020 to May 2021) of 104 deals worth $23.4 billion.

Hellman & Friedman LLC; The Blackstone Group Inc; The Carlyle Group Inc.; GIC Pvt Ltd to acquire a majority stake in Medline Industries Inc. for a consideration of approximately $34 billion was the big-ticket deal, which contributed 68.4 per cent of the total deal value in June 2021. Other top deals during the period were Danaher Corporation to acquire Aldevron LLC, a manufacturer and supplier of plasmid DNA (deoxyribonucleic acid), proteins, enzymes, antibodies, and other biologicals for $9.4 billion and MorphoSys AG, a commercial-stage biopharmaceutical company to acquire Constellation Pharmaceuticals Inc, a clinical-stage biopharmaceutical company developing novel therapeutics, which selectively modulate gene expression to address serious unmet medical needs in patients with cancer for $1.7 billion.

Deal Date Acquirer (s) Target Deal Value ($ m)
05-Jun-21 Hellman & Friedman LLC (US); The Blackstone Group Inc (US); The Carlyle Group Inc. (US); GIC Pvt Ltd (Singapore) Medline Industries Inc (US) 34,000.0
17-Jun-21 Danaher Corp (US) Aldevron LLC (US) 9,600.0
02-Jun-21 MorphoSys AG (Germany) Constellation Pharmaceuticals Inc (US) 1,700.0
22-Jun-21 Big Cypress Acquisition Corp (US) SAB Biotherapeutics Inc (US) 325.0
01-Jun-21 Veracyte Inc (US) HalioDx SAS (France) 317.3

VC investments decreased by six per cent in June 2021, compared to May 2021

The healthcare industry reported 139 venture capital (VC) deals worth $4.5 billion in June 2021, compared to the last 12-month average (June 2020 to May 2021) of 166 deals worth $4.9 billion.

InSilico Medicine Inc, raising $255 million to progress its current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities; Umoja BioPharma Inc, an oncology company raising $210 million Series B financing to continue development of its integrated technologies, advance its product candidates based on CAR T-cell adapter-mediated tumor-targeting (TumorTag) and the in vivo modification of immune cells (VivoVec and RACR/CAR) into clinical development; and Stemirna Therapeutics Ltd, raising $200 million to finance clinical trials and production of its COVID-19 vaccine development are the major VC deals reported in May 2021.

Deal Date Acquirer (s) Target Deal Value ($ m)
22-Jun-21 Maison Capital Group; Orbimed Advisors LLC; Sequoia Capital China; Deerfield Management Company LP; Pavilion Capital Partners LLC; President International Development Corporation; Qiming Venture Partners; Warburg Pincus LLC; Sage Partners; Lilly Asia Ventures; Mirae Asset Capital Co Ltd; Bold Capital Partners; Eight Roads Ventures; Sinovation Ventures; Baidu Ventures; Lake Bleu Capital; B Capital Group Management, L.P.; Formic Ventures; CITIC Industrial Investment Fund Management Co Ltd InSilico Medicine Inc (US) 255.0
15-Jun-21 Temasek Holdings (Private) Ltd; Alexandria Venture Investments; RTW Investments LP; Cormorant Asset Management LLC; Emerson Collective (Emmerson Collective); Casdin Capital LLC; MPM Capital Inc; Qiming Venture Partners USA; Presight Capital; DCVC Bio; CaaS Capital Management; SoftBank Vision Fund 2 Umoja BioPharma Inc (US) 210.0
3-Jun-21 CITIC Securities Co Ltd; Sequoia Capital China; China Merchants Group; CMB International Ltd; Everbright Capital Investment Co., Ltd.; OrbiMed Capital, LLC; WuXiAppTec Co Ltd; GuoxinGuotong Fund LLP; Qingsong Capital Stemirna Therapeutics Ltd (China) 200.0
14-Jun-21 Temasek Holdings (Private) Ltd; Boyu Capital Consultancy Co. Ltd; Sequoia Capital China; E Fund Management Co Ltd; LYFE Capital; Legend Capital; Lake Bleu Capital Jiangsu Rec-Biotechnology Co Ltd (China) 156.1
30-Jun-21 Boyu Capital Consultancy Co. Ltd; Orbimed Advisors LLC; Lilly Asia Ventures; Hillhouse Capital Group; Octagon Capital Advisors LP; Zoo Capital; Lyra Capital Pte Ltd Arrivent Biopharma Inc 150.0

Source: GlobalData


Deal trackerhealthcare industrypharma dealspharma M&AsPharma marketVC investments
Comments (0)
Add Comment